Actively Recruiting
Tranexamic Acid in Adult Spinal Deformity Surgery
Led by Hospital for Special Surgery, New York · Updated on 2026-04-28
100
Participants Needed
1
Research Sites
450 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Posterior spinal surgery for adult deformity is associated with high incidence of blood loss and need for blood transfusion and intraoperative blood salvage, with associated increased cost and risk for perioperative complications. Tranexamic acid (TXA) is relatively inexpensive anti-fibrinolytic agent that has been proven effective for decreasing intraoperative blood loss in various surgical specialties. Intravenous TXA (ivTXA) is routinely used at our institution for adult spinal deformity cases. Meanwhile, topical TXA (tTXA) is an attractive alternative/adjunct to ivTXA used with good results in orthopedic arthroplasty and cardiac surgery. To the investigators' knowledge, no data exists in the literature on the use of tTXA in either adult or pediatric spinal deformity surgery. The goal of this study is to determine the role tTXA has an adjunct to ivTXA in decreasing perioperative blood loss, drainage, transfusion requirements and length of stay following adult deformity spine surgery.
CONDITIONS
Official Title
Tranexamic Acid in Adult Spinal Deformity Surgery
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 80 years
- Scheduled for posterior spinal fusion surgery involving 5 or more levels
- Planned fusion extending to the pelvis
You will not qualify if you...
- Use of anterior surgical approach
- History or presence of unrepaired dural tear
- Preoperative autologous blood donation
- Kidney dysfunction (creatinine >1.5 or creatinine clearance <30 ml/min)
- Liver dysfunction (AST or ALT greater than twice the upper limit of normal)
- Seizure disorder or prior seizures
- Blood clots (stroke, TIA, deep vein thrombosis, pulmonary embolism) within 1 year
- Known hypercoagulability conditions
- Coronary artery disease within 1 year (stent, heart attack, positive stress test)
- Atrial fibrillation
- Use of anticoagulant medications that cannot be stopped before surgery
- Bleeding disorders or abnormal coagulation blood tests
- Anemia with hemoglobin less than 10 g/dL
- Color blindness or color vision disturbance
- Leukemia or active cancer
- Religious restrictions against blood transfusion
- Pregnancy or currently breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hospital for Special Surgery
New York, New York, United States, 10021
Actively Recruiting
Research Team
J
Jordan A Gruskay, MD
CONTACT
E
Evangelia Zgonia, BA
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here